Literature DB >> 17439980

A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology.

J B Leverenz1, C E Yu, T J Montine, E Steinbart, L M Bekris, C Zabetian, L K Kwong, V M-Y Lee, G D Schellenberg, T D Bird.   

Abstract

Mutations in the progranulin (GRN) gene have recently been reported as a cause of the frontotemporal dementia (FTD) syndrome. We performed a clinical, neuropathological and molecular genetic study of two families with FTD and the same novel mutation in GRN. Age of onset ranged from 35 to 75 years and all individuals progressed to a severe dementia syndrome with a mean disease duration of approximately 6-10 years. Variable clinical presentations included language impairment, behaviour change or parkinsonism. Seven total autopsies in the families (five in Family 1, two in Family 2) showed gross and microscopic evidence of neuronal loss in the neocortex, striatum, hippocampus and substantia nigra. All cases with material available for immunohistochemistry had cytoplasmic and intranuclear ubiquitin positive, tau negative inclusions that stained best with an antibody to the TDP43 protein. In addition, all but one had evidence of distinctive tau pathology. Two cases in Family 1 also had alpha-synuclein (SNCA) pathology, one with diffuse neocortical inclusions and neurites and unusual striatal cytoplasmic inclusions. Affected persons in both families had the same mutation in GRN (c.709-2A>G). A minigene construct showed that this mutation alters splicing of exon 7 and results in reduced mRNA message in brain. A single GRN mutation in these two families was associated with variable clinical presentations consistent with the FTD syndrome. All cases had ubiquitin/TDP43 immuno-positive inclusions and most had additional tau pathology. Two cases had SNCA pathology. These findings suggest a link between mutations in GRN and aggregation of tau, TDP43 and SNCA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17439980     DOI: 10.1093/brain/awm069

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  54 in total

Review 1.  Biomarkers to identify the pathological basis for frontotemporal lobar degeneration.

Authors:  Murray Grossman
Journal:  J Mol Neurosci       Date:  2011-07-22       Impact factor: 3.444

Review 2.  An updated diagnostic approach to subtype definition of vascular parkinsonism - Recommendations from an expert working group.

Authors:  Ivan Rektor; Nicolaas I Bohnen; Amos D Korczyn; Viktoria Gryb; Hrishikesh Kumar; Milica G Kramberger; Frank-Erik de Leeuw; Zvezdan Pirtošek; Irena Rektorová; Ilana Schlesinger; Jaroslaw Slawek; Peter Valkovič; Branislav Veselý
Journal:  Parkinsonism Relat Disord       Date:  2017-12-29       Impact factor: 4.891

Review 3.  Update on recent molecular and genetic advances in frontotemporal lobar degeneration.

Authors:  Eileen H Bigio
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

4.  Frequency of progranulin mutations in a German cohort of 79 frontotemporal dementia patients.

Authors:  Johannes Carolus Magnus Schlachetzki; Klaus Schmidtke; Jan Beckervordersandforth; Wiktor Borozdin; Christian Wilhelm; Michael Hüll; Jürgen Kohlhase
Journal:  J Neurol       Date:  2009-07-19       Impact factor: 4.849

Review 5.  Pathology in primary progressive aphasia syndromes.

Authors:  Jennifer M Harris; Matthew Jones
Journal:  Curr Neurol Neurosci Rep       Date:  2014-08       Impact factor: 5.081

Review 6.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

7.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

8.  Frontotemporal dementia in a large Swedish family is caused by a progranulin null mutation.

Authors:  Lena Skoglund; RoseMarie Brundin; Tommie Olofsson; Hannu Kalimo; Sofie Ingvast; Elin S Blom; Vilmantas Giedraitis; Martin Ingelsson; Lars Lannfelt; Hans Basun; Anna Glaser
Journal:  Neurogenetics       Date:  2008-10-15       Impact factor: 2.660

9.  Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Variability in familial Parkinson's disease.

Authors:  K Markopoulou; D W Dickson; R D McComb; Z K Wszolek; L Katechalidou; L Avery; M S Stansbury; B A Chase
Journal:  Acta Neuropathol       Date:  2008-04-04       Impact factor: 17.088

10.  The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.

Authors:  Salvatore Spina; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Jill R Murrell; Graham Fraser; Francine Epperson; R Anthony Crowther; Maria G Spillantini; Michel Goedert; Bernardino Ghetti
Journal:  Brain       Date:  2007-12-07       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.